Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
37.9M
-
Number of holders
-
49
-
Total 13F shares, excl. options
-
3.93M
-
Shares change
-
+281K
-
Total reported value, excl. options
-
$12.8M
-
Value change
-
+$922K
-
Put/Call ratio
-
0.01
-
Number of buys
-
13
-
Number of sells
-
-18
-
Price
-
$3.27
Significant Holders of Anixa Biosciences Inc - Common Stock (ANIX) as of Q3 2023
55 filings reported holding ANIX - Anixa Biosciences Inc - Common Stock as of Q3 2023.
Anixa Biosciences Inc - Common Stock (ANIX) has 49 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.93M shares
of 37.9M outstanding shares and own 10.37% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (1.36M shares), UBS Group AG (604K shares), MISSION WEALTH MANAGEMENT, LP (501K shares), GEODE CAPITAL MANAGEMENT, LLC (300K shares), Long Focus Capital Management, LLC (166K shares), BlackRock Inc. (162K shares), STATE STREET CORP (102K shares), Bank of New York Mellon Corp (96.6K shares), RAYMOND JAMES & ASSOCIATES (56.6K shares), and NORTHERN TRUST CORP (53.4K shares).
This table shows the top 49 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.